MANAGEMENT

Dr. Fridkis-Hareli is an immunologist, consultant and inventor with over 25 years of experience in academia and industry. Her areas of expertise include autoimmune and inflammatory diseases with the particular emphasis on cellular and structural immunology, cell- and protein-based assays, in vitro pharmacology and preclinical immunotoxicology. She has held a variety of positions in industry with increasing responsibilities at Resolvyx Pharmaceuticals, Charles River Laboratories, Taligen Therapeutics and Alexion Pharmaceuticals. At Taligen, Dr. Fridkis-Hareli was responsible for the in vitro pharmacology effort and contributed to discovery and development of its drug pipeline leading to acquisition by Alexion. Dr. Fridkis-Hareli is now Founder and President of ATR, LLC, a translational research company providing scientific consulting and laboratory services in immunoassay development to research institutions and biotechnology companies. Dr Fridkis-Hareli holds a Ph.D in Cell Biology and Immunology from the Weizmann Institute of Science, a M.Sc. in Molecular Genetics from Hebrew University, and a B.A. in Biology from Technion-Israel Institute of Technology.

Mr. DiTullio has more than 30 years of experience in the biopharmaceutical industry and has a broad range of scientific, business and corporate development experience. He was the founder of TranXenoGen Inc a company aimed at the development of novel manufacturing technology and Lakewood Amedex Inc, a company develop a novel class of broad spectrum anti-microbials for bacterial infections. As the VP of Product Development for Lakewood Amedex, Mr. DiTullio was responsible for advancing their novel antimicrobials, termed Bisphosphocin®, from the preclinical stage to a Phase 1/2a clinical trial managing all aspects of cGMP manufacturing, preclinical toxicology, regulatory affairs, and clinical trial design. Mr. DiTullio holds a B.S. in Biochemistry and a M. Sc. in Cell Biology from the University of Vermont.